Recent Trends in the Practice of Procedural Sedation Under Local Anesthesia for Catheter Ablation, Gastrointestinal Endoscopy, and Endoscopic Surgery in ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-06-18

AUTHORS

Akiko Matsui, Michihiro Morimoto, Hiroshi Suzuki, Thomas Laurent, Yoko Fujimoto, Yoshimi Inagaki

ABSTRACT

OBJECTIVES: To investigate changes in sedation practice during 2012-2015, using a large health claims database, for catheter ablation (CA), gastrointestinal endoscopic examination (EE), and surgery (ES) after dexmedetomidine (DEX) was approved for procedural sedation in 2013. We assessed the trends of sedative utilization, sedative-analgesic combinations, and, additionally, incidence of complications from 2012 to 2015. METHODS: Using the database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan), annual utilization proportions of the sedatives and sedative-analgesic combinations and occurrence of complications were calculated in patients with a record of local anesthesia and CA, EE, and/or ES but without general anesthesia used on the same day. The sedatives studied were DEX, propofol (PF), midazolam (MDZ), diazepam, flunitrazepam, thiamylal (TIA), thiopental (TIO), and ketamine. RESULTS: DEX was used most often for CA, followed by PF. From 2012 to 2015, the proportion of DEX increased from 30 to 36%, and that of PF slightly decreased from 29 to 27%. The order of utilization proportions did not change for EE or ES. The use of benzodiazepines, particularly MDZ, predominated. The top five sedative-analgesic combination patterns changed during the study period for CA, but not for EE or ES. The most common complications with CA, EE, and ES were bradycardia, nausea and vomiting, and respiratory depression, respectively. There were no changes in the complications' trends for the procedures. CONCLUSION: The approved use of DEX for procedural sedation resulted in changes for CA, but not for EE or ES. The complication trends did not change. More... »

PAGES

137-147

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40801-018-0136-y

DOI

http://dx.doi.org/10.1007/s40801-018-0136-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104878139

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29916196


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan", 
          "id": "http://www.grid.ac/institutes/grid.418567.9", 
          "name": [
            "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsui", 
        "givenName": "Akiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan", 
          "id": "http://www.grid.ac/institutes/grid.418567.9", 
          "name": [
            "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morimoto", 
        "givenName": "Michihiro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan", 
          "id": "http://www.grid.ac/institutes/grid.418567.9", 
          "name": [
            "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suzuki", 
        "givenName": "Hiroshi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Study Support, Inc, Daiei Bldg., 2F, 1-11-20 Nishiki, Naka-ku, Nagoya, Aichi 460-0003 Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Clinical Study Support, Inc, Daiei Bldg., 2F, 1-11-20 Nishiki, Naka-ku, Nagoya, Aichi 460-0003 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laurent", 
        "givenName": "Thomas", 
        "id": "sg:person.0736342751.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736342751.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan", 
          "id": "http://www.grid.ac/institutes/grid.418567.9", 
          "name": [
            "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujimoto", 
        "givenName": "Yoko", 
        "id": "sg:person.01216450244.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216450244.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Anesthesiology and Clinical Care Medicine, Department of Surgery, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, Tottori 683-8503 Japan", 
          "id": "http://www.grid.ac/institutes/grid.265107.7", 
          "name": [
            "Division of Anesthesiology and Clinical Care Medicine, Department of Surgery, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, Tottori 683-8503 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inagaki", 
        "givenName": "Yoshimi", 
        "id": "sg:person.01257511361.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257511361.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/cc712", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051258507", 
          "https://doi.org/10.1186/cc712"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-002-1338-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002941822", 
          "https://doi.org/10.1007/s00134-002-1338-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-06-18", 
    "datePublishedReg": "2018-06-18", 
    "description": "OBJECTIVES: To investigate changes in sedation practice during 2012-2015, using a large health claims database, for catheter ablation (CA), gastrointestinal endoscopic examination (EE), and surgery (ES) after dexmedetomidine (DEX) was approved for procedural sedation in 2013. We assessed the trends of sedative utilization, sedative-analgesic combinations, and, additionally, incidence of complications from 2012 to 2015.\nMETHODS: Using the database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan), annual utilization proportions of the sedatives and sedative-analgesic combinations and occurrence of complications were calculated in patients with a record of local anesthesia and CA, EE, and/or ES but without general anesthesia used on the same day. The sedatives studied were DEX, propofol (PF), midazolam (MDZ), diazepam, flunitrazepam, thiamylal (TIA), thiopental (TIO), and ketamine.\nRESULTS: DEX was used most often for CA, followed by PF. From 2012 to 2015, the proportion of DEX increased from 30 to 36%, and that of PF slightly decreased from 29 to 27%. The order of utilization proportions did not change for EE or ES. The use of benzodiazepines, particularly MDZ, predominated. The top five sedative-analgesic combination patterns changed during the study period for CA, but not for EE or ES. The most common complications with CA, EE, and ES were bradycardia, nausea and vomiting, and respiratory depression, respectively. There were no changes in the complications' trends for the procedures.\nCONCLUSION: The approved use of DEX for procedural sedation resulted in changes for CA, but not for EE or ES. The complication trends did not change.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40801-018-0136-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1051855", 
        "issn": [
          "2199-1154", 
          "2198-9788"
        ], 
        "name": "Drugs - Real World Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "sedative analgesic combination", 
      "catheter ablation", 
      "endoscopic examination", 
      "procedural sedation", 
      "local anesthesia", 
      "complication trends", 
      "large health claims database", 
      "Medical Data Vision Co.", 
      "incidence of complications", 
      "use of dexmedetomidine", 
      "health claims database", 
      "gastrointestinal endoscopic examination", 
      "occurrence of complications", 
      "retrospective database study", 
      "use of benzodiazepines", 
      "respiratory depression", 
      "common complication", 
      "general anesthesia", 
      "claims database", 
      "gastrointestinal endoscopy", 
      "sedation practices", 
      "dexmedetomidine", 
      "database study", 
      "clinical practice", 
      "propofol", 
      "endoscopic surgery", 
      "complications", 
      "sedation", 
      "anesthesia", 
      "midazolam", 
      "study period", 
      "utilization proportion", 
      "same day", 
      "surgery", 
      "sedatives", 
      "thiamylal", 
      "ablation", 
      "proportion", 
      "vomiting", 
      "nausea", 
      "bradycardia", 
      "patients", 
      "ketamine", 
      "endoscopy", 
      "diazepam", 
      "benzodiazepines", 
      "incidence", 
      "flunitrazepam", 
      "depression", 
      "combination patterns", 
      "database", 
      "examination", 
      "changes", 
      "days", 
      "practice", 
      "use", 
      "combination", 
      "ES", 
      "period", 
      "trends", 
      "records", 
      "study", 
      "occurrence", 
      "procedure", 
      "recent trends", 
      "patterns", 
      "utilization", 
      "Japan", 
      "order", 
      "Ltd.", 
      "Co.", 
      "sedative utilization", 
      "Data Vision Co.", 
      "Vision Co.", 
      "annual utilization proportions", 
      "proportion of DEX", 
      "sedative-analgesic combination patterns"
    ], 
    "name": "Recent Trends in the Practice of Procedural Sedation Under Local Anesthesia for Catheter Ablation, Gastrointestinal Endoscopy, and Endoscopic Surgery in Japan: A Retrospective Database Study in Clinical Practice from 2012 to 2015", 
    "pagination": "137-147", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104878139"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40801-018-0136-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29916196"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40801-018-0136-y", 
      "https://app.dimensions.ai/details/publication/pub.1104878139"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_782.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40801-018-0136-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0136-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0136-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0136-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0136-y'


 

This table displays all metadata directly associated to this object as RDF triples.

185 TRIPLES      22 PREDICATES      105 URIs      95 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40801-018-0136-y schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N7ca355183efa46faa2e745a20551d582
4 schema:citation sg:pub.10.1007/s00134-002-1338-y
5 sg:pub.10.1186/cc712
6 schema:datePublished 2018-06-18
7 schema:datePublishedReg 2018-06-18
8 schema:description OBJECTIVES: To investigate changes in sedation practice during 2012-2015, using a large health claims database, for catheter ablation (CA), gastrointestinal endoscopic examination (EE), and surgery (ES) after dexmedetomidine (DEX) was approved for procedural sedation in 2013. We assessed the trends of sedative utilization, sedative-analgesic combinations, and, additionally, incidence of complications from 2012 to 2015. METHODS: Using the database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan), annual utilization proportions of the sedatives and sedative-analgesic combinations and occurrence of complications were calculated in patients with a record of local anesthesia and CA, EE, and/or ES but without general anesthesia used on the same day. The sedatives studied were DEX, propofol (PF), midazolam (MDZ), diazepam, flunitrazepam, thiamylal (TIA), thiopental (TIO), and ketamine. RESULTS: DEX was used most often for CA, followed by PF. From 2012 to 2015, the proportion of DEX increased from 30 to 36%, and that of PF slightly decreased from 29 to 27%. The order of utilization proportions did not change for EE or ES. The use of benzodiazepines, particularly MDZ, predominated. The top five sedative-analgesic combination patterns changed during the study period for CA, but not for EE or ES. The most common complications with CA, EE, and ES were bradycardia, nausea and vomiting, and respiratory depression, respectively. There were no changes in the complications' trends for the procedures. CONCLUSION: The approved use of DEX for procedural sedation resulted in changes for CA, but not for EE or ES. The complication trends did not change.
9 schema:genre article
10 schema:inLanguage en
11 schema:isAccessibleForFree true
12 schema:isPartOf N0ec8babf60304fb98c803e535a828aaf
13 N4fb2fafb86134abdbc368170e08f02cb
14 sg:journal.1051855
15 schema:keywords Co.
16 Data Vision Co.
17 ES
18 Japan
19 Ltd.
20 Medical Data Vision Co.
21 Vision Co.
22 ablation
23 anesthesia
24 annual utilization proportions
25 benzodiazepines
26 bradycardia
27 catheter ablation
28 changes
29 claims database
30 clinical practice
31 combination
32 combination patterns
33 common complication
34 complication trends
35 complications
36 database
37 database study
38 days
39 depression
40 dexmedetomidine
41 diazepam
42 endoscopic examination
43 endoscopic surgery
44 endoscopy
45 examination
46 flunitrazepam
47 gastrointestinal endoscopic examination
48 gastrointestinal endoscopy
49 general anesthesia
50 health claims database
51 incidence
52 incidence of complications
53 ketamine
54 large health claims database
55 local anesthesia
56 midazolam
57 nausea
58 occurrence
59 occurrence of complications
60 order
61 patients
62 patterns
63 period
64 practice
65 procedural sedation
66 procedure
67 propofol
68 proportion
69 proportion of DEX
70 recent trends
71 records
72 respiratory depression
73 retrospective database study
74 same day
75 sedation
76 sedation practices
77 sedative analgesic combination
78 sedative utilization
79 sedative-analgesic combination patterns
80 sedatives
81 study
82 study period
83 surgery
84 thiamylal
85 trends
86 use
87 use of benzodiazepines
88 use of dexmedetomidine
89 utilization
90 utilization proportion
91 vomiting
92 schema:name Recent Trends in the Practice of Procedural Sedation Under Local Anesthesia for Catheter Ablation, Gastrointestinal Endoscopy, and Endoscopic Surgery in Japan: A Retrospective Database Study in Clinical Practice from 2012 to 2015
93 schema:pagination 137-147
94 schema:productId N93e231779cea4cce87c8e8ff4b24afc7
95 Ne47509c3f15c448d9d69ec3fa5238ae0
96 Nf44361b556634441980dae478d399460
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104878139
98 https://doi.org/10.1007/s40801-018-0136-y
99 schema:sdDatePublished 2021-12-01T19:42
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N2026f57ac9af4adba7204c8c09694757
102 schema:url https://doi.org/10.1007/s40801-018-0136-y
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N0ec8babf60304fb98c803e535a828aaf schema:issueNumber 3
107 rdf:type schema:PublicationIssue
108 N2026f57ac9af4adba7204c8c09694757 schema:name Springer Nature - SN SciGraph project
109 rdf:type schema:Organization
110 N2089308b071b4586af7594f01e3ed494 rdf:first sg:person.0736342751.97
111 rdf:rest Nfafbf23ca4c140ab9c264bcab35725a5
112 N33816605c56d468a994a2715d27f044f schema:affiliation grid-institutes:grid.418567.9
113 schema:familyName Matsui
114 schema:givenName Akiko
115 rdf:type schema:Person
116 N4fb2fafb86134abdbc368170e08f02cb schema:volumeNumber 5
117 rdf:type schema:PublicationVolume
118 N57bcc38b0bf54a65920864a6d403b825 rdf:first N58c5dae591bc4ec4844e86b31dd7147a
119 rdf:rest N2089308b071b4586af7594f01e3ed494
120 N58c5dae591bc4ec4844e86b31dd7147a schema:affiliation grid-institutes:grid.418567.9
121 schema:familyName Suzuki
122 schema:givenName Hiroshi
123 rdf:type schema:Person
124 N66655d8138384efcb35c743b69508a0b rdf:first sg:person.01257511361.01
125 rdf:rest rdf:nil
126 N6740dac2590048c89a40df483a77b3c8 schema:affiliation grid-institutes:grid.418567.9
127 schema:familyName Morimoto
128 schema:givenName Michihiro
129 rdf:type schema:Person
130 N7ca355183efa46faa2e745a20551d582 rdf:first N33816605c56d468a994a2715d27f044f
131 rdf:rest N9cdc1db0bd2c43009b0ff7ef73e21787
132 N93e231779cea4cce87c8e8ff4b24afc7 schema:name doi
133 schema:value 10.1007/s40801-018-0136-y
134 rdf:type schema:PropertyValue
135 N9cdc1db0bd2c43009b0ff7ef73e21787 rdf:first N6740dac2590048c89a40df483a77b3c8
136 rdf:rest N57bcc38b0bf54a65920864a6d403b825
137 Ne47509c3f15c448d9d69ec3fa5238ae0 schema:name pubmed_id
138 schema:value 29916196
139 rdf:type schema:PropertyValue
140 Nf44361b556634441980dae478d399460 schema:name dimensions_id
141 schema:value pub.1104878139
142 rdf:type schema:PropertyValue
143 Nfafbf23ca4c140ab9c264bcab35725a5 rdf:first sg:person.01216450244.20
144 rdf:rest N66655d8138384efcb35c743b69508a0b
145 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
146 schema:name Medical and Health Sciences
147 rdf:type schema:DefinedTerm
148 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
149 schema:name Clinical Sciences
150 rdf:type schema:DefinedTerm
151 sg:journal.1051855 schema:issn 2198-9788
152 2199-1154
153 schema:name Drugs - Real World Outcomes
154 schema:publisher Springer Nature
155 rdf:type schema:Periodical
156 sg:person.01216450244.20 schema:affiliation grid-institutes:grid.418567.9
157 schema:familyName Fujimoto
158 schema:givenName Yoko
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216450244.20
160 rdf:type schema:Person
161 sg:person.01257511361.01 schema:affiliation grid-institutes:grid.265107.7
162 schema:familyName Inagaki
163 schema:givenName Yoshimi
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257511361.01
165 rdf:type schema:Person
166 sg:person.0736342751.97 schema:affiliation grid-institutes:None
167 schema:familyName Laurent
168 schema:givenName Thomas
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736342751.97
170 rdf:type schema:Person
171 sg:pub.10.1007/s00134-002-1338-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1002941822
172 https://doi.org/10.1007/s00134-002-1338-y
173 rdf:type schema:CreativeWork
174 sg:pub.10.1186/cc712 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051258507
175 https://doi.org/10.1186/cc712
176 rdf:type schema:CreativeWork
177 grid-institutes:None schema:alternateName Clinical Study Support, Inc, Daiei Bldg., 2F, 1-11-20 Nishiki, Naka-ku, Nagoya, Aichi 460-0003 Japan
178 schema:name Clinical Study Support, Inc, Daiei Bldg., 2F, 1-11-20 Nishiki, Naka-ku, Nagoya, Aichi 460-0003 Japan
179 rdf:type schema:Organization
180 grid-institutes:grid.265107.7 schema:alternateName Division of Anesthesiology and Clinical Care Medicine, Department of Surgery, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, Tottori 683-8503 Japan
181 schema:name Division of Anesthesiology and Clinical Care Medicine, Department of Surgery, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, Tottori 683-8503 Japan
182 rdf:type schema:Organization
183 grid-institutes:grid.418567.9 schema:alternateName Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan
184 schema:name Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan
185 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...